[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341874-105":59,"doc-detail-341874-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nkg2d-natural-killer-group-2-member-d-ligand-expression-and-ameloblastoma-recurrence-a-retrospective-immunohistological-pilot-study","NKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma recurrence: a retrospective immunohistological pilot study","","Retrospective immunohistological analysis examined how natural killer group 2, member D (NKG2D) ligand expression relates to ameloblastoma recurrence after surgical resection. Formalin-fixed paraffin-embedded tumor tissues from 96 histologically confirmed patients were evaluated by immunohistochemistry for UL16-binding proteins (ULBPs) 1–3 and MHC class I chain-related molecule (MIC) A/B. Electronic medical records were reviewed, and multivariate Cox regression estimated adjusted hazard ratios with 95% confidence intervals. Recurrent tumors and positive MICA/B expression were found to influence recurrence-free survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nkg2d-natural-killer-group-2-member-d-ligand-expression-and-ameloblastoma-recurrence-a-retrospective-immunohistological-pilot-study/341874/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nkg2d-natural-killer-group-2-member-d-ligand-expression-and-ameloblastoma-recurrence-a-retrospective-immunohistological-pilot-study/341874.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal regarding NKG2D ligands and ameloblastoma?","Question",{"text":112,"@type":113},"To investigate how NKG2D ligand expression influences ameloblastoma recurrence after surgical resection and to identify additional clinical predictors of recurrence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which NKG2D ligands were assessed in tumor tissues?",{"text":117,"@type":113},"The study evaluated UL16-binding proteins (ULBPs) 1–3 and major histocompatibility complex class I chain-related molecule (MIC) A/B using immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors were identified as independent predictors of early ameloblastoma recurrence?",{"text":121,"@type":113},"The findings indicate recurrent cases and loss of MICA/B expression as independent predictors of early recurrence following surgery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341874,1790180330,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Kim etal. BMCOral Health (2024) 24:1102 BMC Oral Health  \n[https://doi.org/10.1186/s12903-024-04873-8](https://doi.org/10.1186/s12903-024-04873-8)  \nRESEARCH Open Access  \nNKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma  \nrecurrence: a retrospective immunohistological pilot study  \nMee-seon Kim 1, Soeun Jeon2,3*, Hyeon Jeong Lee4,5, Hyun-Su Ri6, Ah-Reum Cho4,5, Eun Ji Park4,5, Jin Song Yeo6, Jae-Han Kim7 and Jiyoun Lee8  \nAbstract  \nBackground/Purpose This retrospective immunohistological pilot study aimed to investigate the influence of natural killer group 2, member D (NKG2D) ligand expression on ameloblastoma recurrence after surgical resection. It also aimed to elucidate additional clinical factors that could serve as predictors of ameloblastoma recurrence. Materials and methods This study included 96 patients who were histologically diagnosed with ameloblastoma after surgical resection. The expression of NKG2D ligands, including UL16-binding proteins (ULBPs) 1–3 and major histocompatibility complex class I chain-related molecule (MIC) A/B, was evaluated in formal in-fixed paraffinembedded tumor tissues via immunohistochemistry assays. Furthermore, the patients’ electronic medical records were reviewed. Multivariate Cox regression analysis was conducted, and data were expressed as adjusted hazard ratios [HRs] with 95% confidence intervals [95% CIs] .  \nResults Multivariate analysis revealed that recurrent tumors (ref.: primary; adjusted HR [95% CI]: 2.780 [1 . 136, 6. 803], p = 0 . 025) and positive MICA/B expression (ref.: negative; adjusted HR [95% CI]: 0.223 [0 . 050, 0 . 989], p = 0 . 048) independently affected recurrence-free survival in ameloblastoma.  \nConclusion This study identified recurrent cases and loss of MICA/B expression as independent predictors of early ameloblastoma recurrence following surgical resection. The findings suggest that decreased MICA/B expression might undermine NKG2D-mediated tumor immunosurveillance, thereby influencing early recurrence.  \nKeywords Ameloblastoma, Odontogenic tumors, Killer cells, natural, Cytotoxicity, immunologic  \n*Correspondence: Soeun Jeon [jseanes@knu.ac.kr](jseanes@knu.ac.kr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nKim et al. BMC Oral Health (2024) 24:1102  \nIntroduction  \nAmeloblastoma, though rare, is one of the most frequently occurring odontogenic tumors, predominantly located in the mandible and maxilla. Despite being classified as “benign,” ameloblastoma poses a significant challenge due to its marked local invasiveness and high potential for recurrence [1]. The primary therapeutic approach for ameloblastoma is surgical resection [2, 3]. Nevertheless, recurrence remains a significant concern despite meticulous surgical intervention [2, 3]. The known risk factors for ameloblastoma recurrence include maxillary location, large","cbCaipadXKqaKfwG","https://ap.wps.com/l/cbCaipadXKqaKfwG","pdf",2239833,11,"English","# Abstract\n# Introduction\n# Materials and methods\n## Study design, subjects, and ethical considerations","[{\"question\":\"What was the study’s main goal regarding NKG2D ligands and ameloblastoma?\",\"answer\":\"To investigate how NKG2D ligand expression influences ameloblastoma recurrence after surgical resection and to identify additional clinical predictors of recurrence.\"},{\"question\":\"Which NKG2D ligands were assessed in tumor tissues?\",\"answer\":\"The study evaluated UL16-binding proteins (ULBPs) 1–3 and major histocompatibility complex class I chain-related molecule (MIC) A/B using immunohistochemistry.\"},{\"question\":\"What factors were identified as independent predictors of early ameloblastoma recurrence?\",\"answer\":\"The findings indicate recurrent cases and loss of MICA/B expression as independent predictors of early recurrence following surgery.\"}]","NKG2D (Natural Killer Group 2, Member D) ligand expression and ameloblastoma recurrence: a retrospective immunohistological pilot study | PDF",1790044233,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71e6d16dcc7fd87034228a3cf2ed5b48.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/480f9e2912b842af2fc58eb2f66d9141.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71396dd26ab75f2d0cf9bb6d6b90df13.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52c219e9d8e5d3553d5794c47915b492.webp",980,1306]